Articles

April 26, 2021 Diversity Equity & Inclusion at Alnylam: Building on the Momentum to Create Lasting Impact ... Sara Nochur, Alnylam's Chief Diversity, Equity & Inclusion Officer talks about DE&I at Alnylam and her role leading the company's efforts. Read More ›
April 15, 2021 Guest Post: Partnering to Make a Positive Difference for People with Kidney Disease LaVarne Burton, President and CEO of the American Kidney Fund talks about the importance of partnerships... Read More ›
March 12, 2021 Decades of Pain and Uncertainty: Donna’s AHP Story For more than 20 years, Donna navigated debilitating pain, mysterious symptoms and uncertainty about her health. Today, with a better handle on her wellbeing... Read More ›
March 11, 2021 Alnylam Publishes First Corporate Responsibility Summary Today, we've published Alnylam's first Corporate Responsibility Summary detailing our approach to corporate responsibility and the actions we are and intend... Read More ›
March 2, 2021 When Are Kidney Stones a Red Flag? According to some estimates, every 1 in 10 adults in the U.S. experiences a kidney stone, suggesting that kidney stones can be rather prevalent. But when are... Read More ›
February 23, 2021 Rare Disease Day 2021: Rare Is Many. Rare Is Strong. Rare Is Proud. While some aspects of living with a rare disease are similar, there is no singular shared experience. There is, however, a common sentiment among those... Read More ›
February 15, 2021 Recapping Alnylam's 2020 DE&I Speaker Series Launched in 2019, the DE&I Speaker Series welcomes external speakers to Alnylam to share their experiences and perspectives on different topics related to... Read More ›
February 6, 2021 Alnylam Named to Bloomberg's 2021 Gender-Equality Index Alnylam has been selected to Bloomberg's Gender-Equality Index for 2021 Read More ›
December 7, 2020 Alnylam Publishes Its 1st-Ever Rare Disease Trend Report Alnylam's 2020 Rare Disease Trend Report features findings from interviews with 30 U.S. payer and plan decision-makers about barriers to orphan drug access. Read More ›
December 7, 2020 Alnylam Releases 2nd Annual Patient Access Philosophy Report The 2020 Alnylam Patient Access Philosophy Report details Alnylam's progress against key metrics related to patient access to its innovative RNAi therapeutics. Read More ›
Subscribe to Articles

Get In Touch

Have any questions or comments about the content you see on this page?

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site